EP4687907A2 - Dosierungsplan eines her2-inhibitors - Google Patents

Dosierungsplan eines her2-inhibitors

Info

Publication number
EP4687907A2
EP4687907A2 EP24717127.5A EP24717127A EP4687907A2 EP 4687907 A2 EP4687907 A2 EP 4687907A2 EP 24717127 A EP24717127 A EP 24717127A EP 4687907 A2 EP4687907 A2 EP 4687907A2
Authority
EP
European Patent Office
Prior art keywords
compound
cancer
administered
daily dose
daily
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24717127.5A
Other languages
English (en)
French (fr)
Inventor
Anke Baum
Krzysztof CHYLINSKI
Neil Gibson
Ralph NEUMUELLER
Behbood SADROLHEFAZI
Dirk Scharn
Lukas SCHROETER
Josep SERRA FIBLA
Ute VON WANGENHEIM
Sven WIND
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of EP4687907A2 publication Critical patent/EP4687907A2/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
EP24717127.5A 2023-03-29 2024-03-28 Dosierungsplan eines her2-inhibitors Pending EP4687907A2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP23382299 2023-03-29
EP23383067 2023-10-19
EP23383302 2023-12-15
EP24382331 2024-03-27
PCT/EP2024/058464 WO2024200637A2 (en) 2023-03-29 2024-03-28 Dosing schedule of a her2 inhibitor

Publications (1)

Publication Number Publication Date
EP4687907A2 true EP4687907A2 (de) 2026-02-11

Family

ID=90719285

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24717127.5A Pending EP4687907A2 (de) 2023-03-29 2024-03-28 Dosierungsplan eines her2-inhibitors

Country Status (7)

Country Link
EP (1) EP4687907A2 (de)
KR (1) KR20260004349A (de)
CN (1) CN121263188A (de)
AU (1) AU2024247020A1 (de)
IL (1) IL323596A (de)
MX (1) MX2025011417A (de)
WO (1) WO2024200637A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025132522A1 (en) * 2023-12-20 2025-06-26 Boehringer Ingelheim International Gmbh Anti-cancer combination therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307434B2 (de) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Geänderte antikörper
DE69233254T2 (de) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanisierter Heregulin Antikörper
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
CN107236044B (zh) 2008-04-02 2021-07-02 宏观基因有限公司 HER2/neu-特异性抗体和其使用方法
US11608343B2 (en) * 2020-04-24 2023-03-21 Boehringer Ingelheim International Gmbh Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors

Also Published As

Publication number Publication date
WO2024200637A2 (en) 2024-10-03
WO2024200637A3 (en) 2024-12-05
IL323596A (en) 2025-11-01
CN121263188A (zh) 2026-01-02
AU2024247020A1 (en) 2025-10-30
MX2025011417A (es) 2025-11-03
KR20260004349A (ko) 2026-01-08

Similar Documents

Publication Publication Date Title
TWI775781B (zh) 癌症之治療性及診斷性方法
KR102868124B1 (ko) 암에 대한 치료 및 진단 방법
JP6821693B2 (ja) がんのための治療方法及び診断方法
KR20220133243A (ko) 항 tigit 길항제 항체를 이용한 암의 치료 방법
KR20180008449A (ko) 암에 대한 치료 및 진단 방법
TW202000702A (zh) 用於抗ｔｉｇｉｔ拮抗劑抗體及抗ｐｄ－ｌ１拮抗劑抗體治療之投藥
JP2022058699A (ja) 再発性小細胞肺癌の処置方法において使用するための抗ｐｄ－１抗体
JP2018521019A (ja) 抗ｏｘ４０抗体を使用して癌を治療する方法
JP7399895B2 (ja) Ｐｄ－１軸結合拮抗薬、白金剤、およびトポイソメラーゼｉｉ阻害剤で肺癌を治療する方法
IL323596A (en) HER2 inhibitor dosing schedule
KR20210063330A (ko) 방광암에 대한 치료 및 진단 방법
BR112021000673A2 (pt) métodos para tratar um indivíduo com câncer de pulmão, kits, anticorpo anti-pd-l1 e composições
KR20220070237A (ko) 항-tigit 및 항-pd-l1 길항제 항체를 이용한 치료를 위한 투약
US20250228858A1 (en) Anti-cancer combination therapy
US20230250195A1 (en) Methods for Reducing Infusion-Related Reactions in Patients Treated with EGFR/Met Bispecific Antibodies
US20260034134A1 (en) Treatment of cancer with metastases in the central nervous system
JP2023523450A (ja) 非小細胞肺がん免疫療法のための方法及び組成物
CN111886257A (zh) 用于疾病和病症治疗和预防的抗-肾酶抗体
WO2025051693A1 (en) Cancer treatment with a her2 inhibitor and a cyp3a and/or p-gp modulator
WO2026038160A1 (en) Methods for reducing infusion-related reactions in patients treated with egfr/met bispecific antibodies
CN106714833A (zh) Rspo1结合剂及其用途
CN104762371A (zh) 用于预测或监控c-Met抑制剂效力的生物标志物
HK40053012A (en) Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
HK40002960B (zh) 用於癌症的治疗和诊断方法

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20250908

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR